Skip to main content
Fig. 2 | Molecular Neurodegeneration

Fig. 2

From: CCR5 antagonist reduces HIV-induced amyloidogenesis, tau pathology, neurodegeneration, and blood-brain barrier alterations in HIV-infected hu-PBL-NSG mice

Fig. 2

MVC prevents HIV-induced immunosuppression in infected mice. Levels of human (h)CD4+ (a, b), hCD8+ (c, d) and hCD45+ T-cells in each blood sample were quantified by FACS before (Pre) infection and at week (Wk) -1, − 2, and − 3 post-infection. Levels of hCD4+ and hCD8+ cells in each sample were normalized to the sample’s hCD45+ cells levels. e, f: hCD4+/hCD8+ T-cells ratios. The four animal groups included NSG mice engrafted with human PBL, uninfected and untreated (PBS), uninfected and treated with MVC (MVC), infected with HIV-1ADA and untreated (HIV), or treated with MVC (HIV + MVC). Sample size: 9 to 11 animals in each group. #P < 0.0001, ***P < 0.0007, **P = 0.0013. For all panels, error bars represent standard deviation (SD)

Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326